AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Chimeric Therapeutics has appointed Dr. Rebecca McQualter as CEO, effective immediately.
- McQualter has extensive experience in regenerative medicine and cell therapy.
- The company has three CAR T and NK cell assets in four Phase 1/1b clinical trials.
Chimeric Therapeutics Ltd. (ASX:CHM), a cancer cell therapy company, has appointed Dr. Rebecca McQualter, its Chief Operating Officer, as CEO, effective 12 November 2024.
Dr. McQualter holds extensive expertise specialising in regenerative medicine and cell therapy. She has held senior roles at international firms such as Novartis, Amgen, and GlaxoSmithKline. Throughout her career, she has demonstrated a proven ability to build commercial partnerships and strong networks with stakeholders across the healthcare and pharmaceutical industries.
Clinical Trial Progress
Currently, the company has three CAR T and NK cell assets in four Phase 1/1b clinical trials.
Image source: Company update
CHM CDH17, a first-in-class, 3rd generation CDH17 CAR T, received FDA IND clearance for its Phase 1/2 trial in 2023. This trial, initiated in 2024, is studying the therapy in gastrointestinal and neuroendocrine tumours. The dosing of the first patient has also been completed.
CHM CORE-NK is a clinically validated, off the shelf and enhanced natural killer (NK) cell platform. The acute myeloid leukemia (AML) patient achieved complete response in the CHM CORE-NK + Vactosertib Phase 1b clinical trial.
CHM CLTX, a novel CAR T therapy, is being studied in a phase 1B clinical trial for recurrent / progressive glioblastoma.
CHM shares were trading nearly 10% higher at AU$0.011 each at the time of writing on 12 November 2024.
